Clinical Trials Logo

Filter by:
NCT ID: NCT04243915 Recruiting - Low Back Pain Clinical Trials

Percutaneous Neuromuscular Electrical Stimulation in Patients With Chronic Low Back Pain

PNMESlowback
Start date: April 10, 2021
Phase: N/A
Study type: Interventional

Chronic low back pain is a common musculoskeletal condition affects the general population. Low back pain constitutes a major burden to health care system and society. Several authors have found that the deep abdominal muscles and multifidus are affected in low back pain. Dry needling has shown improve the cross-sectional area of the multifidus. Percutaneous electrical nerve stimulation has shown reduce pain in several conditions. There are not studies that had investigated the impact of percutaneous neuromuscular electrical stimulation (PNMES) in the deep muscles in patients with chronic low back pain. Hypothesis: PNMES in the multifidus muscle plus motor control exercise program in patients with chronic low back pain is better than sham PNMES plus exercise and transcutaneous electrical nerve stimulation (TENS) plus exercise

NCT ID: NCT04243499 Recruiting - Solid Tumor, Adult Clinical Trials

First-in-Human Study of ICT01 in Patients With Advanced Cancer

EVICTION
Start date: February 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.

NCT ID: NCT04241328 Recruiting - Clinical trials for Cardiovascular Diseases

Medtronic SYMBIOSIS Post-Market Registry for Patients Undergoing Cardiac Surgery

SYMBIOSIS
Start date: January 9, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational, multi-center prospective, post-market registry is to confirm real-world device safety and performance, to ensure the continued acceptability of identified risks, and detect emerging risks.

NCT ID: NCT04241185 Recruiting - Clinical trials for Urinary Bladder Neoplasms

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Start date: May 19, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

NCT ID: NCT04241042 Recruiting - Healthy Clinical Trials

Clinical Validation of the Bordeaux Maze Test

BORMATE
Start date: April 5, 2019
Phase:
Study type: Observational

Currently, the instruments used in translational studies related to cognition have proved to be inaccurate. For this reason, the objective of this study is to evaluate whether the Bordeaux Maze Test has adequate psychometric properties and is valid for its use to compare trials tested in preclinical (animal) studies and clinical population with Down syndrome. Specifically, it is intended to study the domains of memory (relational memory) and executive functions (work memory), both relevant in the cognitive functioning of the population with Down syndrome.

NCT ID: NCT04240002 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start date: September 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of the phase 2 portion (dose expansion) is to determine complete remission (CR) rates and composite complete remission (CRc) rates after two cycles of therapy. The study will also assess safety, tolerability and toxicities of gilteritinib in combination with FLAG, evaluate FLT3 inhibition, assess pharmacokinetics (PK), perform serial measurements of minimal residual disease, obtain preliminary estimates of 1-year event free survival (EFS) and overall survival (OS) rate and assess the acceptability as well as palatability of the formulation. One cycle is defined as 28 days of treatment. A participant completing 1 or 2 treatment cycles in phase 1 or 2 will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).

NCT ID: NCT04238884 Recruiting - Clinical trials for Invasive Fungal Infections

Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy

VORIGENPHARM
Start date: January 2, 2020
Phase: Phase 4
Study type: Interventional

This is a phase IV pragmatic, multicentre, randomised, simple-blind, parallel arm, centre-stratified clinical trial. The main objective is to compare efficiency of voriconazole preemptive genotyping strategy, compared with routine practice.

NCT ID: NCT04236765 Recruiting - Clinical trials for Tuberculosis Infection

Tuberculosis In Children Visiting Friends and Relatives

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

In countries with a low incidence of Tuberculosis (TB), the incidence remains higher among the immigrant population than among the autochthonous population beyond the first years after arrival in the host country. In addition, at a pediatric level, most cases are produced in immigrant children and the children of immigrants. This persistence of a greater incidence in the immigrant population might, in part, be explained by the increase in exposure to Mycobacterium tuberculosis during trips to their country of origin to visit friends and relatives (VFRs). The objectives of the study are to estimate the risk of latent infection by M. tuberculosis (LTBI)/TB in children VFRs and the factors associated with this risk. The investigators will also study the behavior of the diagnostic tests. This project will be carried out in collaboration with 21 primary health care centers and 5 hospitals in Catalonia.

NCT ID: NCT04236492 Recruiting - Clinical trials for Osteochondral Defect

Study Protocol to Evaluate Clinical and Imaging Results of Knee Fresh Osteochondral Allografts

Start date: June 6, 2018
Phase:
Study type: Observational

The main objective of this study is to assess the clinical and radiological results after carrying out a transplant of fresh osteochondral allograft in the knee.

NCT ID: NCT04236414 Recruiting - Solid Tumours Clinical Trials

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Start date: January 14, 2020
Phase: Phase 1
Study type: Interventional

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.